These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy. Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645 [TBL] [Abstract][Full Text] [Related]
14. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy. Walker A; Watson C; Alexopoulos ST; Deniz B; Arnold R; Bates D Curr Med Res Opin; 2014 Apr; 30(4):629-35. PubMed ID: 24289170 [TBL] [Abstract][Full Text] [Related]
15. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. van Kempen ZL; Leurs CE; Vennegoor A; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J Mult Scler; 2017 Jun; 23(7):995-999. PubMed ID: 28112019 [TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. Fissolo N; Pignolet B; Matute-Blanch C; Triviño JC; Miró B; Mota M; Perez-Hoyos S; Sanchez A; Vermersch P; Ruet A; de Sèze J; Labauge P; Vukusic S; Papeix C; Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Montalban X; Brassat D; Comabella M; Ann Neurol; 2017 Aug; 82(2):186-195. PubMed ID: 28681388 [TBL] [Abstract][Full Text] [Related]